Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.66 |
| ▸ | MGLL | Q99685 | 8/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252684 | 0.92 | EPHX2 (0.67) | EPHX2MGLLENPP2KMT2A | |
| SCHEMBL7913189 | 0.90 | EPHX2 (0.59) | EPHX2KMT2A | |
| SCHEMBL7921985 | 0.89 | EPHX2 (0.60) | EPHX2MGLLKMT2A | |
| SCHEMBL30089345 | 0.87 | EPHX2 (0.73) | EPHX2KMT2A | |
| SCHEMBL29400630 | 0.87 | EPHX2 (0.73) | EPHX2KMT2A | |
| SCHEMBL118921 | 0.87 | EPHX2 (0.73) | EPHX2KMT2A | |
| SCHEMBL29401210 | 0.86 | EPHX2 (0.63) | EPHX2KMT2A | |
| SCHEMBL118052 | 0.86 | EPHX2 (0.63) | EPHX2KMT2A | |
| SCHEMBL29561956 | 0.86 | EPHX2 (0.63) | EPHX2KMT2A | |
| SCHEMBL10283985 | 0.84 | EPHX2 (0.56) | EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2081888-A1 | N-BIARYL (HETERO) ARYLSULPHONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY LYMPHOCYTES INTERACTIONS | Novartis AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008028937-A1 | N-BIARYL (HETERO) ARYLSULPHONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY LYMPHOCYTES INTERACTIONS | NOVARTIS AG (CH) | 2008-03-13 | — | — | WO | disclosed |
| US-6228985-B1 | COMPOUNDS THAT INHIBIT INTERACTION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR WITH UROKINASE-TYPE PLASMINOGEN RECEPTOR; ANTITUMOR AGENTS; ANTIMETASTASIS AGENTS; ANTIARTHRITIC AGENTS FOR RHEUMATOID ARTHRITIS | SCHERING CORPORATION | 2001-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029609-A1 | BIARYL SULFONAMIDE DERIVATIVES | UGT2B7, CYP3A7, STS | EPHX2 1140/4885MGLL 2400/4885ENPP2 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.